4-Substituted-2,5-dimethoxyamphetamines (DOx) is a chemical class of substituted amphetamine derivatives featuring methoxy groups at the 2- and 5- positions of the phenyl ring, and a substituent such as alkyl or halogen at the 4- position of the phenyl ring. [1] Most compounds of this class are potent and long-lasting psychedelic drugs, and act as highly selective 5-HT2A, 5-HT2B, and 5-HT2C receptor partial agonists. A few bulkier derivatives such as DOAM have similarly high binding affinity for 5-HT2 receptors but instead act as antagonists, and so do not produce psychedelic effects though they retain amphetamine-like stimulant effects.
The DOx family includes the following members:
Structure | Name | Abbreviation | CAS number |
---|---|---|---|
2,5-Dimethoxy-4-amylamphetamine | DOAM | 63779-90-8 | |
2,5-Dimethoxy-4-bromoamphetamine | DOB | 64638-07-9 (racemate) | |
2,5-Dimethoxy-4-butylamphetamine | DOBU | 63779-89-5 | |
2,5-Dimethoxy-4-chloroamphetamine | DOC | 123431-31-2 | |
2,5-Dimethoxy-4-ethoxyamphetamine | MEM | 16128-88-4 | |
2,5-Dimethoxy-4-(methoxymethyl)amphetamine | DOMOM [2] | 260810-10-4 | |
2,5-Dimethoxy-4-(ethoxymethyl)amphetamine | DOMOE | 930836-81-0 | |
2,5-Dimethoxy-4-ethylamphetamine | DOET | 22004-32-6 | |
2,5-Dimethoxy-4-ethylthioamphetamine | Aleph-2 | 185562-00-9 | |
2,5-Dimethoxy-4-fluoroamphetamine | DOF | 125903-69-7 | |
2,5-Dimethoxy-4-(2-fluoroethyl)amphetamine | DOEF | 121649-01-2 | |
2,5-Dimethoxy-4-(3-fluoropropyl)amphetamine | DOPF | ||
2,5-Dimethoxy-4-iodoamphetamine | DOI | 42203-78-1 | |
2,5-Dimethoxy-4-isopropylthioamphetamine | Aleph-4 | 123643-26-5 | |
2,5-Dimethoxy-4-methylamphetamine | DOM | 15588-95-1 | |
2,5-Dimethoxy-4-methylthioamphetamine | Aleph-1 | 61638-07-1 | |
2,5-Dimethoxy-4-nitroamphetamine | DON | 67460-68-8 | |
2,5-Dimethoxy-4-phenylthioamphetamine | Aleph-6 | 952006-44-9 | |
2,5-Dimethoxy-4-benzylamphetamine | DOBZ [3] | 125903-73-3 | |
2,5-Dimethoxy-4-(3-methoxybenzyl)amphetamine | DO3MeOBZ [4] | 930836-90-1 | |
2,5-Dimethoxy-4-[(tetrahydrofuran-2-yl)methyl]amphetamine | DOTHFM | 930776-12-8 | |
2,5-Dimethoxy-4-propylamphetamine | DOPR | 63779-88-4 | |
2,5-Dimethoxy-4-isopropylamphetamine | DOiP | 42306-96-7 | |
2,5-Dimethoxy-4-propylthioamphetamine | Aleph-7 | 207740-16-7 | |
2,5-Dimethoxy-4-(difluoromethyl)amphetamine | DODFM | ||
2,5-Dimethoxy-4-trifluoromethylamphetamine | DOTFM | 159277-07-3 | |
2,5-Dimethoxy-4-(2,2,2-trifluoroethyl)amphetamine | DOTFE [5] | ||
2,5-Dimethoxy-4-cyanoamphetamine | DOCN [6] | 125903-74-4 | |
2,5-Dimethoxy-4-ethynylamphetamine | DOYN [7] | 633290-70-7 | |
A number of additional compounds are known with alternative substitutions:
Structure | Name | Abbreviation | CAS number |
---|---|---|---|
Dimoxamine ("Ariadne") | 4C-D | 52842-59-8 | |
1-(2,5-Dimethoxy-4-ethylphenyl)butan-2-amine [8] | 4C-E | ||
1-(2,5-Dimethoxy-4-(n-propyl)phenyl)butan-2-amine | 4C-P | ||
1-(2,5-Dimethoxy-4-bromophenyl)butan-2-amine | 4C-B | 69294-23-1 | |
1-(2,5-Dimethoxy-4-chlorophenyl)butan-2-amine | 4C-C | 791010-74-7 | |
1-(2,5-Dimethoxy-4-iodophenyl)butan-2-amine | 4C-I | 758631-75-3 | |
1-(2,5-Dimethoxy-4-nitrophenyl)butan-2-amine | 4C-N | 775234-58-7 | |
1-[2,5-Dimethoxy-4-(ethylthio)phenyl]butan-2-amine | 4C-T-2 | 850007-13-5 | |
Dimethoxymethamphetamine ("Beatrice") | N-methyl-DOM | 92206-37-6 | |
2,5-Dimethoxy-3,4-methylenedioxyamphetamine | DMMDA | 15183-13-8 | |
2,5-dimethoxy-3,4-dimethylamphetamine ("Ganesha") | 3-methyl-DOM | 207740-37-2 | |
2,5-Dimethoxy-3,4-trimethylenylamphetamine | G-3 | ||
2,5-Dimethoxy-3,4-tetramethylenylamphetamine | G-4 | ||
2,5-Dimethoxy-3,4-norbornylamphetamine | G-5 | ||
1-(5,8-dimethoxy-3,4-dihydro-1H-isochromen-7-yl)propan-2-amine [9] | G-O | 774538-38-4 | |
2,5-Dimethoxy-3,4-dichloroamphetamine | DODC | 1373918-65-0 | |
IDNNA | IDNNA | 67707-78-2 | |
Methyl-DOB | N-methyl-DOB | 155638-80-5 | |
2,3,4,5-Tetramethoxyamphetamine | 2,3,4,5-Tetramethoxyamphetamine | 23693-26-7 | |
1-(4-Bromo-2,3,6,7-tetrahydrofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine | DOB-FLY | 219986-75-1 | |
Bromo-DragonFLY | DOB-DFLY | 502759-67-3 | |
Compound 1 [10] | |||
Dimethoxybromoamphetamine (DOB), also known as brolamfetamine (INN) and bromo-DMA, is a psychedelic drug and substituted amphetamine of the phenethylamine class of compounds. DOB was first synthesized by Alexander Shulgin in 1967. Its synthesis and effects are documented in Shulgin's book PiHKAL: A Chemical Love Story.
2C-TFM is a psychedelic phenethylamine of the 2C family. It was first synthesized in the laboratory of David E. Nichols. It has also been called 2C-CF3, a name derived from the Para-trifluoromethyl group it contains.
2,5-Dimethoxy-4-ethylamphetamine is a psychedelic drug of the phenethylamine and amphetamine chemical classes. It was first synthesized by Alexander Shulgin, and was described in his book PiHKAL.
2C (2C-x) is a general name for the family of psychedelic phenethylamines containing methoxy groups on the 2 and 5 positions of a benzene ring. Most of these compounds also carry lipophilic substituents at the 4 position, usually resulting in more potent and more metabolically stable and longer acting compounds. Most of the currently known 2C compounds were first synthesized by Alexander Shulgin in the 1970s and 1980s and published in his book PiHKAL. Shulgin also coined the term 2C, being an acronym for the 2 carbon atoms between the benzene ring and the amino group.
2C-H (2,5-dimethoxyphenethylamine) is a lesser-known substituted phenethylamine of the 2C family.
2,5-Dimethoxy-4-butylamphetamine (DOBU) is a lesser-known psychedelic drug and a substituted Amphetamine. DOBU was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), only low dosages of 2–3 mg were tested, with the duration simply listed as "very long". DOBU produces paresthesia and difficulty sleeping, but with few other effects. Compared to shorter chain homologues such as DOM, DOET and DOPR which are all potent hallucinogens, DOBU has an even stronger 5-HT2 binding affinity but fails to substitute for hallucinogens in animals or produce hallucinogenic effects in humans, suggesting it has low efficacy and is thus an antagonist or weak partial agonist at the 5-HT2A receptor.
2,5-Dimethoxy-4-(2-fluoroethyl)amphetamine is a lesser-known psychedelic drug and member of the DOx class. DOEF was first synthesized by Alexander Shulgin. In his book PiHKAL, the dosage range is listed as 2–3.5 mg, and the duration is listed as 12–16 hours. Very little data exists about the pharmacological properties, metabolism, and toxicity of DOEF.
Dimethoxy-4-amylamphetamine (DOAM) is a lesser-known psychedelic drug and a substituted amphetamine. DOAM was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dosage is listed as 10 mg, and the duration is unknown. DOAM produces a bare threshold and tenseness. As the 4-alkyl chain length is increased from shorter homologues such as DOM, DOET, DOPR, and DOBU which are all potent hallucinogens, the 5-HT2 binding affinity increases, rising to a maximum with the 4-(n-hexyl) derivative before falling again with even longer chains, but compounds with chain length longer than n-propyl, or with other bulky groups such as isopropyl, t-butyl or γ-phenylpropyl at the 4- position, fail to substitute for hallucinogens in animals or produce hallucinogenic effects in humans, suggesting these have low efficacy and are thus antagonists or weak partial agonists at the 5-HT2A receptor.
2,5-Dimethoxy-4-ethoxyamphetamine (MEM) is a psychedelic drug of the phenethylamine and amphetamine chemical classes. It was first synthesized by Alexander Shulgin. In his book PiHKAL, he lists the active dose range as 20–50 mg, and the duration as 10–14 hours. According to Shulgin, MEM produces color enhancement, visual phenomena, and pattern movement, among other effects.
MMDA-2 (2-methoxy-4,5-methylenedioxyamphetamine) is a psychedelic drug of the amphetamine class. It is closely related to MMDA and MDA.
2,5-Dimethoxy-4-fluoroamphetamine (DOF) is a psychedelic drug of the phenethylamine and amphetamine classes. Alexander Shulgin briefly describes DOF in his book PiHKAL:
Animal studies that have compared DOF to the highly potent DOI and DOB imply that the human activity will be some four to six times less than these two heavier halide analogues.
5-Methoxy-7,N,N-trimethyltryptamine (5-MeO-7,N,N-TMT, 5-MeO-7-TMT), is a tryptamine derivative which acts as an agonist at the 5-HT2 serotonin receptors. In animal tests, both 7,N,N-TMT and 5-MeO-7,N,N-TMT produced behavioural responses similar to those of psychedelic drugs such as DMT and 5-MeO-DMT, but compounds with larger 7-position substituents such as 7-ethyl-DMT and 7-bromo-DMT did not produce psychedelic-appropriate responding despite high 5-HT2 receptor binding affinity, suggesting these may be antagonists or weak partial agonists for the 5-HT2 receptors. The related compound 7-MeO-MiPT (cf. 5-MeO-MiPT) was also found to be inactive, suggesting that the 7-position has poor tolerance for bulky groups at this position, at least if agonist activity is desired.
Substituted tryptamines, or serotonin analogues, are organic compounds which may be thought of as being derived from tryptamine itself. The molecular structures of all tryptamines contain an indole ring, joined to an amino (NH2) group via an ethyl (−CH2–CH2−) sidechain. In substituted tryptamines, the indole ring, sidechain, and/or amino group are modified by substituting another group for one of the hydrogen (H) atoms.
2C-T-16 is a lesser-known psychedelic drug. It was originally named by Alexander Shulgin as described in his book PiHKAL, however while Shulgin began synthesis of this compound he only got as far as the nitrostyrene intermediate, and did not complete the final synthetic step. Synthesis of 2C-T-16 was finally achieved by Daniel Trachsel some years later, and it was subsequently reported as showing similar psychedelic activity to related compounds, with a dose range of 10–25 mg and a duration of 4–6 hours, making it around the same potency as the better-known saturated analogue 2C-T-7, but with a significantly shorter duration of action. Binding studies in vitro showed 2C-T-16 to have a binding affinity of 44nM at 5-HT2A and 15nM at 5-HT2C. 2C-T-16 and related derivatives are potent partial agonists of the 5-HT1A, 5-HT2A, 5-HT2B and 5-HT2C receptors and induce a head-twitch response in mice.
2,5-Dimethoxy-4-isopropylamphetamine is a psychedelic drug of the phenethylamine and amphetamine chemical classes. It was first synthesized by Alexander Shulgin, and was described in his book PiHKAL. Shulgin described DOiPR as being at least an order of magnitude weaker than DOPr, with doses of 20–30 mg required to produce valid changes in mental state. Very little data exists about the pharmacological properties, metabolism, and toxicity of DOiPR.
2-Bromomescaline (2-Br-M) is a derivative of the phenethylamine hallucinogen mescaline which has an unusual 2-bromo substitution. It is an agonist for serotonin receptors, with a binding affinity of 215 nM at 5-HT1A, 513 nM at 5-HT2A and 379 nM at 5-HT2C, so while it is around ten times more tightly binding than mescaline at 5-HT1A and 5-HT2A receptors, it is over twenty times more potent at 5-HT2C.
The 25-NB (25x-NBx) series, sometimes alternatively referred to as the NBOMe compounds, is a family of serotonergic psychedelics. They are substituted phenethylamines and were derived from the 2C family. They act as selective agonists of the serotonin 5-HT2A receptor. The 25-NB family is unique relative to other classes of psychedelics in that they are, generally speaking, extremely potent and relatively selective for the 5-HT2A receptor. Use of NBOMe series drugs has caused many deaths and hospitalisations since the drugs popularisation in the 2010s. This is primarily due to their high overdose potential and sellers passing off the compounds in the series as LSD.
2,5-dimethoxy-4-bromophenylpiperazine (2C-B-PP) is a drug of the phenylpiperazine class. It acts as an agonist at serotonin receptors, and in studies on rats substituted for the psychedelic amphetamine derivative DOM with around 1/10 the potency but similar rates of stimulus-appropriate responding at the highest dose.
4C-B is a lesser-known psychedelic drug which is related to 2C-B and DOB. It is a reasonably potent 5-HT2A receptor partial agonist with a Ki of 7.6nM, but has relatively low efficacy. It is briefly mentioned in Alexander Shulgin's book PiHKAL but was never tested by him, however it has subsequently been tested by other researchers and was found to be active in a dose range of 50-80mg with a duration of around 8 hours, though with generally milder effects than 2C-B or DOB.
2C-T-3 is a lesser-known psychedelic drug related to compounds such as 2C-T-7 and 2C-T-16. It was named by Alexander Shulgin but was never made or tested by him, and was instead first synthesised by Daniel Trachsel some years later. It has a binding affinity of 11nM at 5-HT2A and 40nM at 5-HT2C. It is reportedly a potent psychedelic drug with an active dose in the 15–40 mg range, and a duration of action of 8–14 hours, with visual effects comparable to related drugs such as methallylescaline.